Carbapenem-Resistant Organisms/Carbapenemase-Producing Organisms - Surveillance Report (2023-11-30)

Carbapenem-Resistant Organisms/Carbapenemase-Producing Organisms - Surveillance Report (2023-05-09)

Carbapenemase Producing Organisms in NM 12/2019 data

This annual report provides an update on prevention progress in 2018.

2019 Facility-Specific Addendum

This report provides information about Improving the Quality of Healthcare-Associated Infection Reporting in New Mexico, 2015-2017.

This annual report provides an update on prevention progress in 2018.

2018 Facility-Specific Addendum

This annual report provides an update on prevention progress in 2017.

2017 Facility-Specific Addendum

HAI prevention progress is tracked using a standardized infection ratio which compares the current number of infections to the number of predicted infections based on national baseline data; lower SIRs indicate better progress (i.e., fewer infections). National prevention targets are set by US Department of Health and Human Services and through the Healthy People framework.

2016 Facility-Specific Addendum

Healthcare-associated infections are recognized as a complication of modern medicine and a source of significant morbidity and mortality among hospitalized individuals. Among the HAIs, Clostridium difficile infection incidence has increased markedly in the past decade and now has become the most common HAI pathogen. Furthermore, Clostridium difficile contributes to health care costs with a recent source estimated the attributable cost to be $3427 to $9960 per episode for acute care hospitals.

This annual report provides an update on prevention progress in 2015.

2015 Facility-Specific Addendum

This annual report provides an update on prevention progress in 2014.

2014 Facility-Specific Addendum

This annual report provides an update on prevention progress in 2013.

This annual report provides an update on prevention progress in 2012.

This annual report provides an update on prevention progress in 2011.

The objectives of the Phase 2 Healthcare-associated Infection and Antimicrobial Use Prevalence Survey were to work out logistical issues with survey methodology and procedures, estimate Healthcare-associated infections prevalence among inpatients in acute healthcare facilities, determine distribution of Healthcare-associated infections by pathogen and major infection site, and estimate prevalence and describe rationale for antimicrobial use in acute healthcare facilities.

This annual report provides an update on prevention progress in 2010.

This pilot report includes six hospitals located in Albuquerque, Alamogordo, Farmington and Las Cruces whom voluntarily submit data about the number of central line-associated bloodstream infections in their adult intensive care units and influenza vaccination of their healthcare workers.